Arcus Biosciences is a company creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of researchers from the biotechnology and pharmaceutical industries.

Biotechnology

Arcus Biosciences

Dr. Parsey is currently the Chief Medical Officer of [Gilead Sciences](/org/gilead-sciences), where he is responsible for overseeing Gilead’s global clinical development and medical affairs organizations. Prior to joining Gilead, Dr. Parsey served as Senior Vice President of Early Clinical Development at [Genentech](/org/genentech), where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to [Genentech](/org/genentech), Dr. Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences). Prior to Sagimet BioSciences, Dr. Parsey held development roles at Sepracor, [Regeneron](/org/regeneron) and [Merck](/org/merck) and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at [Stanford University](/org/stanford) and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado. He currently also serves on the Board of Directors for Sagimet BioSciences.

Merdad Parsey

Katherine Bock

Yvonne Gehring

Nigel Walker

Matt Walters

Patty Carlos

Jason Barker

Lixia Jin

Melissa C. Paoloni

Jay has had a remarkable track record of success in drug discovery in the biopharmaceutical industry, spanning a period of nearly 20 years. Most recently, Jay was Vice President of Drug Discovery at Flexus Biosciences and then FLX Bio. During his tenure at Flexus, he oversaw drug design efforts in the IDO Inhibitor program, which was the main driver for the company’s acquisition by BMS in early 2015. Previously, he was Vice President of Drug Discovery at [ChemoCentryx](/org/chemocentryx). During his tenure there of just under 7 years, Jay was involved in the discovery and clinical progression of 7 novel drug candidates in the immunology area, the most advanced of which is currently undergoing Phase 3 evaluation in ANCA-associated renal vasculitis. Prior to joining [ChemoCentryx](/org/chemocentryx) in 2007, Jay was at Tularik and then [Amgen](/org/amgen) (after its acquisition of Tularik in 2004), most recently as Scientific Director in Medicinal Chemistry. Jay began his career in 1996, working in the anti-infectives area at Abbott Laboratories.

Jay Powers

Andrew Pennell

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded [Arcus](/org/arcus), a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, Dr. Rosen was co-founder and CEO of Flexus Biosciences, focusing on small molecule drugs that reverse tumor immunosuppression. He has held several executive positions at [Amgen](/org/amgen) and Tularik, as well as scientific and management positions at [Pfizer](/org/pfizer) and Abbott Laboratories. Dr. Rosen also serves on the boards of scientific institutions such as the Salk Institute Board of Trustees and the Caltech Biology & Engineering Chair’s Council.


Terry Rosen

Dr. Perlman has been a long-time leader in the biotechnology field. Dr. Perlman served as Senior Director of Clinical Research at [Genentech](/org/genentech) contributing to their early success, including playing a key role in the development, FDA approval and marketing of Nutropin® (somatropin). He was one of the first hires at Tularik, with a broad array of responsibilities that early on included clinical trial design and implementation, ultimately expanding to include key roles in Tularik’s business development, investor relations and financing activities, culminating with Tularik’s acquisition by [Amgen](/org/amgen) in 2004. Dr. Perlman’s experience also included serving as CEO of Affymax. He is currently Managing Director and Head of non-clinical Development of X-37, LLC, an artificial intelligence-enabled drug discovery company, as well as the Chief Medical Officer and Managing Director of [Velocity Pharmaceutical Development](/org/velocity-pharmaceutical-development). Dr. Perlman earned his M.D. and Ph.D. degrees from [New York University](/org/nyu), and carried out post-doctoral research in the laboratory of Nobel Laureate Professor Eric Kandel. He completed his post-graduate clinical training at NYU and Stanford School of Medicine.



Andy Perlman

Dr. Nuyten is a physician-scientist with broad experience built over 15 years across all phases of drug development. He joined Arcus in August 2022 from Chief Medical Officer roles at Nektar Therapeutics and Aduro Biotech. Until 2019, he was Vice President and Immuno-Oncology Development Leader at Pfizer, responsible for the full development program and registrational strategy for Bavencio® and the development of multiple immuno-oncology programs. Earlier in his career, he led early development for immuno-oncology at Pfizer and served as Group Medical Director at Bristol-Myers Squibb in the early development oncology group. Dr. Nuyten received his M.D. from the University of Groningen and his Ph.D. from the University of Amsterdam. He trained as a radiation oncologist at the Netherlands Cancer Institute in Amsterdam and was a visiting scientist at Stanford University from 2004-2005.

Dimitry S.A. Nuyten

After several years as a member of the Arcus Scientific Advisory Board, in 2020 Jonathan joined Arcus as Senior Vice President, Research. As a member of the Research Leadership team, Jonathan provides guidance to all aspects of the research, discovery, and translational efforts, creating a key research interface with the Development organization.

Throughout Jonathan’s long tenure in the pharmaceutical/biotech industry, he has held senior leadership positions in the R&D organizations of several pillars of the sector, including BMS (VP, Oncology Discovery & Translational Research), and Lilly (VP Oncology Research and then VP Translational Science & Technology), as well as innovative biotech companies Idera Pharmaceuticals (CSO) and Bind Therapeutics (CSO). He has applied his extensive scientific expertise in oncology and translational research to the discovery and development of multiple cancer drugs. He also established and led global research and translational science partnerships in the U.S., Singapore, China, and Europe. In addition, he championed and led major merger and acquisition transactions. Jonathan has been involved in the discovery and development of more than 15 drug candidates, including galunisertib and merestinib.

Jonathan Yingling

Dr Ribas is an internationally recognized physician-scientist who conducts translational and clinical research aimed at understanding how the immune system can be used to treat cancer. He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered T cells, and BRAF-targeted therapies. His efforts have been instrumental in transforming the treatment paradigm for oncology patients, particularly those with malignant melanoma, having served as principal investigator for multiple trials, including those involving the breakthrough cancer therapy, Keytruda®.

Dr Ribas is Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center, and Director of the Parker Institute for Cancer Immunotherapy Center at UCLA. He is currently the President-Elect for the American Association for Cancer Research (AACR). Dr Ribas has founded or advised several successful biopharma companies in addition to [Arcus](/org/arcus), such as Kite Pharma and Flexus Biosciences. Most recently, he co-founded [PACT Pharma](/org/pact-pharma), a company developing personalized cancer neoantigen-targeted T cell therapies, together with Professors David Baltimore and Jim Heath and [Arcus](/org/arcus) co-founders, Terry Rosen and Juan Jaen. Dr Ribas has been a member of the [Arcus](/org/arcus) Scientific Advisory Board since its creation in 2015.

Dr Ribas received MD and PhD degrees from the Universidad de Barcelona (Spain). He completed his internship and residency in medical oncology at the University Hospital Vall d’Hebron (Barcelona, Spain) and conducted postdoctoral research at UCLA. Following a fellowship in hematology/oncology in the Department of Medicine at UCLA, he has held numerous faculty and administrative positions at UCLA since 2001. Dr Ribas has received a myriad of awards and honors, including the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the AACR Richard and Hinda Rosenthal Award and the National Cancer Institute (NCI) Outstanding Investigator Award. Dr Ribas has also served on the Board of Directors of leading scientific organizations such as the AACR and the Society for Immunotherapy for Cancer (SITC).

Antoni Ribas

During his 17-year tenure at [Amgen](/org/amgen), Dr. Lacey oversaw [Amgen](/org/amgen)’s Discovery Research organization during a key period in the company’s history, leading more than 1,200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience. At [Amgen](/org/amgen), Dr. Lacey helped make significant advancements in the understanding of bone biology, playing a fundamental role in the discovery of osteoprotegerin (OPG) and in the understanding of the RANK/RANK ligand pathway in bone metabolism that paved the way for the development of Prolia® (denosumab) for osteoporosis and XGEVA® for cancer-­related bone diseases, which had combined annual sales of more than $2 billion. Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product. Dr. Lacey also initiated the clinical studies of keratinocyte growth factor (KGF), which ultimately was approved as Kepivance® (palifermin) for chemotherapy patients with severe oral mucositis. Prior to joining [Amgen](/org/amgen), Dr. Lacey was on the faculty at Washington University Medical Center in St. Louis, Missouri where he taught pathology residents and medical students, performed professional medical service in anatomic pathology, and pursued NIH-funded research in bone cell biology.

Dr. Lacey received his bachelor’s degree in biology and his M.D. degree from the University of Colorado where he served as Chief Resident of Anatomic Pathology in his final year of training. He is board certified in anatomical pathology. Dr. Lacey currently serves as a Board member for several biotech companies and acts as an esteemed advisor to a number of academic institutions, biotechnology companies, and venture capital firms.

David Lacey

Mr Machado has served as a member of our board since December 2019. Mr Machado has over two decades of experience growing biopharmaceutical organizations from development through commercialization. He has extensive operational experience, having led finance, business development, and legal functions at multiple companies. Mr Machado co-founded and served as CFO and CBO at Medivation until his retirement in 2014 and served as a member of Medivation’s Board of Directors from 2014 until its acquisition for approximately $14 billion by [Pfizer](/org/pfizer) in 2016. During his tenure at Medivation, Mr Machado helped lead the company through substantial growth and challenges, providing strong leadership during the clinical development and successful commercial launch of Xtandi® in prostate cancer.

Prior to Medivation, Mr Machado worked at ProDuct Health, where he held positions as CFO, Senior Vice President of Business Development and General Counsel; Mr Machado was also responsible for working with national health plans in the US to expand access to patients in need of ductal lavage. Earlier in his career, Mr Machado served as chief legal counsel to the Chiron Technologies business unit at Chiron Corporation and led the transaction teams for all substantial Chiron Technologies collaborations. Prior to joining Chiron, Mr Machado worked for Morrison & Foerster LLP, a leading international law firm, and for the Massachusetts Supreme Judicial Court.

Mr Machado received his JD degree from Harvard Law School and holds both a BS degree in Economics and a BA degree in German from [Santa Clara University](/org/santa-clara-university) in California.

Patrick Machado

Dr Kaneko has served as a member of our board of directors since May 2015. Dr Kaneko has been a managing director at Skyline Venture Partners, a venture capital firm, since 1999. Previously, Dr Kaneko served on the board of LeukoSite, a biopharmaceutical company, until its merger with Millennium Pharmaceuticals in 1999. Dr Kaneko also served as CFO and Vice President, Business Development at Tularik, a biopharmaceutical company, from 1992 until 1998. Dr Kaneko served as a Senior Vice President and CFO of [Ionis Pharmaceuticals](/org/ionis-pharmaceuticals), a biopharmaceutical company, which went public in May 1991 during his tenure. Dr Kaneko began his career at [Genentech](/org/genentech), where he served in a business development role, a biotechnology company, and as head of corporate finance in the investment banking division of Paribas Capital Markets LTD in Tokyo.

Dr Kaneko received an undergraduate degree and an MD degree from Keio University in Tokyo, and an MBA from Stanford Business School. He currently serves as a member of the Dean of Research Advisory Council at [Stanford University](/org/stanford).

Yasunori Kaneko

Dr Garcia is an investigator at the [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute). He also serves as a professor at the Stanford University School of Medicine across 2 departments (Molecular and Cellular Physiology; Structural Biology).

Christopher Garcia

Ms Falberg has served as a member of the board since September 2017. Previously, she served as Executive Vice President and CFO of [Jazz Pharmaceuticals](/org/jazz-pharmaceuticals), a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and CFO since December 2009. Her responsibilities at [Jazz Pharmaceuticals](/org/jazz-pharmaceuticals) included strategy, corporate development, corporate communications, and information technology. From 1995 to 2001, Ms Falberg was with [Amgen](/org/amgen), a biotechnology company, where she served as Senior Vice President, Finance and Strategy, and CFO; and prior to that she was Vice President, Chief Accounting Officer, and Treasurer. Ms Falberg currently serves as a member of the Board of Directors for the public biopharmaceutical companies [Aimmune Therapeutics](/org/aimmune-therapeutics), [aTyr Pharma](/org/atyr-pharma), Axovant Sciences and [The Trade Desk](/org/the-trade-desk), and recently served on the Board of Directors of Medivation until its acquisition by [Pfizer](/org/pfizer).

Kathryn Falberg

Dr Bluestone serves as the chairman of [Arcus](/org/arcus)'s Scientific Advisory Board. He is CEO and President of [Sonoma Biotherapeutics](/org/sonoma-biotherapeutics) and an A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology at University of California, San Francisco.

Jeffrey A. Bluestone

Ms Jarrett has served as a member of our board since January 2019. Ms Jarrett currently serves as Vice President, Corporate Development and Capital Markets at [Uber](/org/uber) and is responsible for all of their M&A and capital markets activities. Most recently, she served as CFO and COO at [Arcus Biosciences](/org/arcus-biosciences), where she was responsible for finance, accounting, investor relations, strategy, human resources and business development. Ms Jarrett played an important role in leading [Arcus](/org/arcus)’s initial public offering. Prior to joining [Arcus](/org/arcus), she served as CFO at Medivation until its acquisition by [Pfizer](/org/pfizer) in 2016.

Prior to Medivation, Ms Jarrett spent 20 years in investment banking, most of that time covering biotechnology companies. Ms Jarrett served as a Managing Director at [Citigroup](/org/citigroup) where she headed up their west coast life sciences investment banking group. Ms Jarrett also worked in the investment banking divisions of [Credit Suisse](/org/credit-suisse), Donaldson, Lufkin & Jenrette, Merrill Lynch, and Kidder Peabody. Ms Jarrett currently serves on the Board of Directors of [Arena Pharmaceuticals](/org/arena-pharmaceuticals), Audentes Therapeutics and Syndax Pharmaceuticals.

Jennifer Jarrett

Dr Spranger is currently an Assistant Professor of Biology at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.

Stefani Spranger

Linda Higgins, Ph.D., currently serves as Senior Vice President of Research, External Innovation at Gilead Sciences, Inc. Dr. Higgins joined Gilead in 2010 and in her first nine years led Biology, leading a significant expansion of the therapeutic area scope and capabilities of the department.

Prior to joining Gilead, Dr. Higgins previously served as the President & CEO of InteKrin Therapeutics and as Head of Research at Scios, Inc., a Johnson & Johnson company, where she provided leadership for drug discovery, preclinical development, and translational medicine. Dr. Higgins obtained her BA degree in Behavioral Physiology from Kenyon College and her Ph.D. in Neuroscience from the University of California, San Diego School of Medicine, and conducted her post-doctoral research in Molecular Genetics at the Howard Hughes Medical Institute at the University of California, Berkeley. Dr. Higgins currently serves on the Supervisory Board of Galapagos and the Board of Directors of Tizona Therapeutics.

Linda Higgins

Nicole Lambert is the president of Myriad Genetic Laboratories. Prior to her current position, she served as general manager for the Oncology and Urology business units and vice president of Dermatology. Prior to joining Myriad, she was a genetic counselor at LabCorp. Mrs. Lambert received her bachelor’s degree in Biology and Sociology from Boston College and she earned her master’s in genetic counseling from Mt. Sinai School of Medicine at New York University.

Nicole Lambert

Ms Tang is an attorney with broad expertise in transactions, intellectual property, securities and corporate governance (US and Europe). Prior to joining [Arcus](/org/arcus), Carolyn was responsible for strategic transactions, securities and corporate governance at Medivation, until its acquisition by [Pfizer](/org/pfizer). Prior to Medivation, Ms Tang held positions of increasing responsibility at InterMune, where she oversaw the company’s global IP portfolio and supported the approval and commercialization of Esbriet® as a treatment for idiopathic pulmonary fibrosis in the EU, Canada, and US. She helped establish and administer InterMune’s European subsidiaries and assisted in public offerings of common stock and convertible senior notes raising nearly $850 million in the 4 years prior to the company’s acquisition by Roche.

Carolyn Tang

Dr Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded [Arcus Biosciences](/org/arcus-biosciences) together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by [Bristol-Myers Squibb](/org/bristol-myers-squibb) for $1.25 billion. Previously, he was CSO and Senior Vice President of Drug Discovery at [ChemoCentryx](/org/chemocentryx). During his tenure there of just under 7 years, Dr Jaen led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. From 1996 to 2006, Dr Jaen held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then [Amgen](/org/amgen) (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry. From 1983 to 1996, Dr Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert.

Juan Jaen

Steve has been in scientific, technical and leadership roles across Europe and the US since 1993, most recently as VP of Technology at Flexus Biosciences (subsequently FLX Bio). He was the first scientist at Flexus and spearheaded a ground-up build of the biology and IT/informatics functions, including hiring the team and establishing the SAR data infrastructure which enabled the successful IDO inhibitor program. Previously, as Executive Director at [Amgen](/org/amgen), heading the Discovery Technologies Department, Steve led a group of 110 scientists across five geographical sites to enact key technical functions including Research Automation and Technology, Materials Management, HTS, Bioassay Technology and Target Discovery/Validation. Steve started at [Amgen](/org/amgen) in 2004, following the acquisition of Tularik, where he had been leading the Lead Discovery Function (Small Molecule and Genomic Screening, Automation and SAR data generation). He moved to Seattle to establish the first automated screening laboratory at [Amgen](/org/amgen), Washington in 2006.

In 2008 he moved again to Massachusetts to serve as the inaugural site head at [Amgen](/org/amgen)’s east coast research hub in Cambridge, focusing on [Amgen](/org/amgen)’s growth in a key scientific locale and acting as [Amgen](/org/amgen)’s senior representative for academia, industry and government affairs. Prior to moving to the U.S. in 2001, Steve headed the HTS Department at Roche U.K., having started his career earlier at Glaxo. Steve holds B.Sc. (Hons) and Ph.D. degrees in Biochemistry from the [University of Bristol](/org/university-of-bristol) and a diploma in Business Administration from the Open University. He is currently on the Board of Directors of the Society for Laboratory Automation and Screening.

Steve Young

Mr. Matthews has more than 20 years of experience in biopharmaceuticals in roles spanning global product strategy, marketing, and product development as well as US marketing and sales leadership. Over his career, he has launched 15 new medicines, including Avastin®, Tarceva®, Tecentriq®, and Imfinzi®. Prior to joining Arcus, Mr. Matthews was with AstraZeneca and Roche/Genentech where he worked on first-in-class immunotherapy products and novel therapeutic combinations. He has also worked as a Congressional Health Policy Analyst and was involved in developing the Medicare Modernization Act.

Eric Matthews

Mr. Goeltz has an extensive track record and breadth of experience in finance and accounting, most recently serving as Chief Financial Officer and Senior Vice President of UNITY Biotechnology and immediately before that as Chief Financial Officer of CytomX Therapeutics, leading both of the companies’ IPOs and finance organizations. Prior to these positions, Mr. Goeltz had an 11-year tenure at Amgen, holding positions including the Chief Financial Officer of Onyx Pharmaceuticals after its acquisition by Amgen, and senior financial roles in commercial and R&D finance, business development, and accounting. In his roles at Amgen, he was involved in multiple oncology product launches. Earlier in his career, he served as Director of Finance for Tularik. Mr. Goeltz began his career in the audit practice of EY. Mr. Goeltz received his Master of Business Administration degree from UCLA’s Anderson School of Management and his Bachelor of Business Administration degree from Emory University’s Goizueta School of Business.

Bob Goeltz

Dr. Tholudur is an accomplished biotechnology professional with over 22 years of CMC experience and a demonstrated track record of leading cross-functional teams in successfully commercializing biopharmaceutical products. He joined Arcus in February 2021 and currently leads the Pharmaceutical Development & Manufacturing organization that is responsible for developing robust, reliable, and efficient manufacturing processes/test methods and ensuring that Arcus’s medicinal products are manufactured to the highest standards in strong compliance with quality and regulatory expectations. Prior to Arcus, Dr. Tholudur spent over 15 years at Amgen in various roles of increasing responsibility in Process Development in the areas of drug substance, secondary packaging, technology transfers, technical operations, and product strategy.

Arcus Biosciences

About

Photos

Values

Insider experiences

Org chart

Teams

Jobs

Wires

Similar organizations